Activation of Factor XII and Kallikrein-Kinin System Combined with Neutrophil Extracellular Trap Formation in Diabetic Retinopathy

Abstract

Background In diabetic retinopathy (DR), neutrophil extracellular traps (NET) and kallikrein-kinin system are considered as contributing factors. However, the detail activation mechanisms has not been fully understood. Since the NET could provide negative-charged surface for factor XII activation and the activated factor XII (XIIa) can initiate kallikrein-kinin system, this study investigated whether patients with DR show activation of NET, factor XII and kallikrein-kinin system.

Methods The markers related to NET (DNA-histone complex) and kallikrein-kinin system (high-molecular-weight kininogen, prekallikrein, bradykinin) and factor XIIa were measured in 253 patients with diabetes. To access ex vivo effect of glucose, DNA-histone complex and factor XIIa were measured in whole blood stimulated by glucose.

Results The circulating level of DNA-histone complex and factor XIIa were significantly higher in patients with DR than those without DR. In logistic regression analysis, DNA-histone complex, factor XIIa, and high-molecular-weight kininogen were the risk factors of DR. In recursive partitioning analysis, among patients with diabetes duration less than 10 years, patients with high level of DNA-histone complex (>426 AU) showed high risk of DR. In ex vivo experiment, glucose significantly elevated both DNA-histone complex and factor XIIa.

Conclusion Our findings suggest that activation of factor XII and kallikrein-kinin system combined with NET formation actively occur in patients with DR and circulating levels of DNA-histone complex, factor XIIa and HMWK can be potential biomarkers to estimate the risk of DR. Strategies against factor XII activation may be beneficial to inhibit DR.

Keywords

diabetic retinopathy - factor XII - kallikrein-kinin system

Publication History

Received: 25 June 2019
Received: 19 July 2019

Accepted: 22 July 2019

Article published online:
19 August 2019

• References

• 1 Klein R, Klein BEK. Diabetic eye disease. The Lancet 1997; 350: 197-204
• 2 Hendrick AM, Gibson MV, Kulshreshtha A. Diabetic retinopathy. Prim Care 2015; 42: 451-464
• 3 Shurtz-Swirski R, Sela S, Herskovits AT. et al. Involvement of peripheral polymorphonuclear leukocytes in oxidative stress and inflammation in type 2 diabetic patients. Diabetes Care 2001; 24: 104-110
• 4 Phipps JA, Feener EP. The kallikrein-kinin system in diabetic retinopathy: Lessons for the kidney. Kidney Int 2008; 73: 1114-1119
• 5 Leshner M, Wang S, Lewis C. et al. PAD4 mediated histone hypercitrullination induces heterochromatin decondensation and chromatin unfolding to form neutrophil extracellular trap-like structures. Front Immunol 2012; 3: 307
• 6 Park JH, Kim JE, Gu JY. et al. Evaluation of circulating markers of neutrophil extracellular trap (NET) formation as risk factors for diabetic retinopathy in a case-control association study. Exp Clin Endocrinol Diabetes 2016; 124: 557-561
• 7 Pixley R, Sainz I, Colman R. Fifty years of research on the plasma kallikrein-kinin system: from protein structure and function to cell biology and in-vivo pathophysiology. Thromb and Haemost 2017; 98: 77-83
• 8 Liu J, Feener EP. Plasma kallikrein-kinin system and diabetic retinopathy. Biol Chem 2013; 394: 319-328
• 9 Clermont A, Chilcote TJ, Kita T. et al. Plasma kallikrein mediates retinal vascular dysfunction and induces retinal thickening in diabetic rat. Diabetes 2011; 60: 1590-1598
• 10 Abdulaal M, Haddad NM, Sun JK. et al. The role of plasma kallikrein-kinin pathway in the development of diabetic retinopathy: Pathophysiology and therapeutic approaches. Semin Ophthalmol 2016; 31: 19-24
• 11 Fuchs TA, Brill A, Duerschmied D. et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci USA 2010; 107: 15880-15885
• 12 Barliya T, Dardik R, Nisgav Y. et al. Possible involvement of NETosis in inflammatory processes in the eye: Evidence from a small cohort of patients. Mol Vis 2017; 23: 922-932
• 13 Hothorn T, Hornik K, Zeileis A. Unbiased recursive partitioning: A conditional inference framework. J Comput Graph Stat 2006; 15: 651-674
• 14 Goldmann O, Medina E. The expanding world of extracellular traps: Not only neutrophils but much more. Front Immunol 2012; 3: 420
• 15 Sela S, Shurtz-Swirski R, Awad J. et al. The involvement of peripheral polymorphonuclear leukocytes in the oxidative stress and inflammation among cigarette smokers. Isr Med Assoc J 2002; 4: 1015-1019
• 16 Miyoshi A, Yamada M, Shida H. et al. Circulating neutrophil extracellular trap levels in well-controlled type 2 diabetes and pathway involved in their formation induced by high-dose glucose. Pathobiology 2016; 83: 243-251
• 17 Menegazzo L, Ciciliot S, Poncina N. et al. NETosis is induced by high glucose and associated with type 2 diabetes. Acta Diabetol 2015; 52: 497-503
• 18 Berezin A.. Neutrophil extracellular traps: The core player in vascular complications of diabetes mellitus. Diabetes Metab Syndr 2019; 13: 3017-3023
• 19 Gupta AK, Joshi MB, Philippova M. et al. Activated endothelial cells induce neutrophil extracellular traps and are susceptible to NETosis-mediated cell death. FEBS Lett 2010; 584: 3193-3197
• 20 Muller F, Renne T. Novel roles for factor XII-driven plasma contact activation system. Curr Opin Hematol 2008; 15: 516-521
• 21 Murugesan N, Ustunkaya T, Feener EP. Thrombosis and hemorrhage in diabetic retinopathy: A perspective from an inflammatory standpoint. Semin Thromb Hemost 2015; 41: 659-664
• 22 Schmaier AH. The contact activation and kallikrein/kinin systems: Pathophysiologic and physiologic activities. J Thromb Haemost 2016; 14: 28-39
• 23 Fadini GP, Menegazzo L, Rigato M. et al. NETosis delays diabetic wound healing in mice and humans. Diabetes 2016; 65: 1061-1071
• 24 Carestia A, Frechtel G, Cerrone G. et al. NETosis before and after hyperglycemic control in type 2 diabetes mellitus patients. PLoS One. 2016; 11: e0168647
• 25 Weitz JI. Factor XI and factor XII as targets for new anticoagulants. Thromb Res 2016; 141 Suppl 2 S40-S45
• 26 Nickel KF, Long AT, Fuchs TA. et al. Factor XII as a therapeutic target in thromboembolic and inflammatory diseases. Arterioscler Thromb Vasc Biol 2017; 37: 13-20
• 27 Simo-Servat O, Simo R, Hernandez C. Circulating biomarkers of diabetic retinopathy: An overview based on physiopathology. J Diabetes Res 2016; 2016: 5263798
• 28 Wujak L, Didiasova M, Zakrzewicz D. et al. Heparan sulfate proteoglycans mediate factor XIIa binding to the cell surface. J Biol Chem 2015; 290: 7027-7039